News

Researchers at John Hopkins Medicine have announced they have identified a gene that guides the separation of two types of motion-sensing cells, offering insight into how cellular layering develops in the retina, with possible implications for the brain’s cerebral cortex.

New study results show using genetic testing and phenotypic evaluations together in patients with drusen can increase the likelihood of determining who may develop advanced AMD.

A new agent aimed at treating symptomatic vitreomacular adhesion can affect patients differently depending on several components.

PIONEER study results find that intraoperative optical coherence tomography is vital for vitreoretinal surgery and recovery.

A better understanding of how genetic risk factors influence the trajectory of age-related macular degeneration may be key to solving the puzzles of this disease. Ocular tissue research may play a role in that process.

Ultra-widefield fluorescein angiography may help improve treatment in patients with recalcitrant diabetic macular edema by visualizing areas of peripheral nonperfusion that can benefit from targeted photocoagulation.

Efficacy and practical limitations of subthreshold laser treatment for diabetic macular edema.

Lasers continue to have a place in the treatment of diabetic macular edema with foveal involvement despite the advent of anti-VEGF therapy.

The therapeutic pipeline for neovascular age-related macular degeneration (AMD) contains a host of promising investigational agents. Only time will tell how any one will shape the future of AMD management.

Though the scenic backdrop of the Pacific Northwest at this year’s meeting of the Association for Research in Vision and Ophthalmology (ARVO) may have been different from the traditional Floridian seascape, the meeting’s world-class science continues to be at the forefront.

Much has changed since the early days of vitrectomy, as exemplified in ophthalmic texts

United Kingdom’s National Institute for Health and Care Excellence (NICE) has provisionally recommended ocriplasmin (Jetrea, ThromboGenics NV) for reimbursement within the National Health Service (NHS).

What is your diagnosis?

The Cole Eye Institute will present a Retina Summit CME symposium immediately before the ARVO 2013 annual meeting.

Optos plc has received 510(k) clearance from the FDA for microperimetry as part of the OptosOCT SLO.

Gene therapy is making headway in inherited retinal diseases that were previously thought to be untreatable.